Yahoo! Groups Tips
Did you know...
Hear how Yahoo! Groups has changed the lives of others. Take me there.
|
Read on!
Nelson Vergel
Director, Program for Wellness Restoration (PoWeR)
An all volunteer non profit organization
www.powerusa.org
AIDS is not over. There are 40 million people infected with HIV and 20 million people have died so far while 14,000 people are infected every day. Only 5% of those needing treatment get it. Most PWAs in the world are dying helplessly while rich nations watch. We will be remembered by future generations as the people who allowed greed and profits to be more important than human suffering and lives.
|
PoWeRTX@...
nelsonvergel
 Offline
 Send Email
|
|
|
Top News Articles
Friday, March 12, 2004
|
 |
|
|
Enfuvirtide (Fuzeon; formerly T-20) is the first fusion (entry) inhibitor to be approved by the US Food and Drug Administration (FDA) for the treatment of HIV infection. Currently, most HIV physicians reserve use of this new drug for AIDS patients who are heavily treatment-experienced and/or who have few or no treatment options due to the development of multidrug-resistant HIV.  |
Safety and Efficacy of Enfuvirtide (Fuzeon) as Part of an HIV Treatment Regimen in Children and Adolescents
Researchers in the US and in San Juan, Puerto Rico are conducting Study T20-310, an ongoing phase I/II pharmacokinetic, safety, and efficacy study of enfuvirtide/ ENF (Fuzeon) in combination with an optimized background in HIV-infected children and adolescents. Preliminary results of the study were presented at the 11th CROI in San Francisco (February 8-11, 2004). |
Cutaneous Injection Site Reactions to Long-term Therapy with Enfuvirtide (Fuzeon)
Enfuvirtide (Fuzeon) is the first fusion (entry) inhibitor, a new class of antiretroviral agents. The drug is safe and well tolerated. Injection site reactions are the most common adverse events. The aim of this study was to conduct a clinical and histopathological evaluation of injection site reactions in patients treated with enfuvirtide for 80 weeks. |
|
|
|
| Light and moderate Alcohol Intake May Have Minimal or No Effect on Fibrosis Development in HCV Infection |
|
|
| Study Findings Support Use of Interferon Alfa as First Line Therapy for HBeAg Positive Hepatitis B Patients with Compensated Liver Disease |
|
|
Enfuvirtide (Fuzeon), the First Fusion Inhibitor for Treatment of HIV: Overview and Review of the Literature
Safety and Efficacy of Enfuvirtide as Part of an HIV Treatment Regimen in Adolescents
Cutaneous Injection Site Reactions to Long-term Therapy with Enfuvirtide (Fuzeon)
Are Immunosuppressive Drugs a Useful Adjuvant to Treatment of HIV with Antiretrovirals?
HAART May Make Suppressive Therapy for Cryptococcal Meningitis Unnecessary
Ceramide Is Overproduced in HIV Dementia |
| The Doctor Is In - Questions from Readers and Answers by Medical Experts |
|
  "I tested undetectable for HCV after the 12th shot [of interferon] and remained the same for the rest of the therapy. Should I have the HCV RNA QUANT PCR TEST done?"
"I'm HIV-HCV coinfected and have lipodystrophy and also have fluid in my stomach. Now that I am HCV undetectable, will this will clear out on its own?"
"Is the sale of unused prescription drugs such as PEG-Intron illegal?"
"How long can hepatitis B and C viruses live in air, water, ethyl alcohol. Can they be killed with soap or petroleum oils?" |
|
|
|
"Ronald Baker, Publisher" <steven@...>
steven@...
Send Email
|
|
Having problems with message search?
Fill out this form to ensure your group is one of the first to be migrated to the new message search system.
